Table 1.
Baseline demographics and characteristics of all enrolled patients
| Patients (N=32) | |
| Median age, years | 60 (27–69) |
| Sex | |
| Male | 18 (56) |
| Female | 14 (44) |
| Stage at enrollment | |
| Unresectable | 1 (3) |
| Primary metastatic | 6 (19) |
| Recurrent/metastatic | 25 (78) |
| Histology | |
| GBCA | 6 (19) |
| Intra-CCA | 11 (34) |
| Perihilar CCA | 6 (19) |
| Distal CCA | 9 (28) |
| ECOG performance status | |
| 0–1 | 30 (94) |
| 2 | 2 (6) |
| Diameter of the largest target lesion (cm) | |
| <5 | 18 (56) |
| ≥5 | 14 (44) |
| Sum of target lesions (cm) | |
| <10 | 20 (62) |
| ≥10 | 12 (38) |
| Sites of metastases | |
| Liver | 28 (88) |
| Lung | 5 (16) |
| Abdominal lymph node | 21 (66) |
| Previous treatment | |
| Surgery | 21 (66) |
| Locoregional therapy | 10 (31) |
| Chemotherapy | 7 (22) |
| None | 7 (22) |
| Tumor PD-L1 expression | |
| <1% | 14 (44) |
| ≥1% | 12 (37) |
| Not assessable | 6 (19) |
Data are n (%), unless otherwise specified.
Histology was categorized according to the WHO Classification of Tumors.
CCA, cholangiocarcinoma; ECOG, Eastern Cooperative Oncology Group; GBCA, gallbladder carcinoma; PD-L1, programmed cell death-ligand 1.